Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -12.50 -5.38% 220.00 69,577 16:35:19
Bid Price Offer Price High Price Low Price Open Price
225.00 232.00 232.50 220.00 231.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.51 -9.78 -13.36 152
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:19 UT 2,500 220.00 GBX

Oncimmune (ONC) Latest News

More Oncimmune News
Oncimmune Investors    Oncimmune Takeover Rumours

Oncimmune (ONC) Discussions and Chat

Oncimmune (ONC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-16 15:35:19220.002,5005,500.00UT
2021-04-16 15:22:59226.989212,090.49O
2021-04-16 15:21:34227.005,00011,350.00O
2021-04-16 15:05:32222.755001,113.75O
2021-04-16 14:59:02223.002,5005,575.00O
View all Oncimmune trades in real-time

Oncimmune (ONC) Top Chat Posts

Oncimmune Daily Update: Oncimmune Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ONC. The last closing price for Oncimmune was 232.50p.
Oncimmune Holdings Plc has a 4 week average price of 171.50p and a 12 week average price of 157.50p.
The 1 year high share price is 260.50p while the 1 year low share price is currently 68.50p.
There are currently 69,097,540 shares in issue and the average daily traded volume is 118,920 shares. The market capitalisation of Oncimmune Holdings Plc is £152,014,588.
someuwin: From the above interview... Roche bought GenMark Diagnostics 3 weeks ago for 1.8bn. Exact Sciences bought Thrive for 2bn. And GRAIL was bought by Illumina for 8bn. Plus Oxford Nanopore are to list for 4bn - 7bn. So, as ONC CEO Adam Hill says,'this space is really hot'.
waterloo01: Cheers. Didn't know you were also into ONC. We met once Timbo at an IMM AGM. I was the one asking most of the questions.
burtond1: Here, @DDS_DocHoliday recently caught up with @OncimmuneECDT CEO Dr. Adam Hill. #ONC profiles the body's immune response to detect evidence of the body's natural response to cancer.In a fascinating interview Hill explains a little more...
pugugly: What the hell is a "foothil contract" New one on me - never come across before - Neither it appears has Google!!
dave444: You do realize that ONC are not a pure play on Covid19?They might get a small amount of revenue from helping pharma companies test things but will not be making it themselves
dave444: What has that got to do with ONC?
andymunchkin: COdey Posts: 2,724 Price: 66.50 No Opinion RE: Nice18 Feb 2020 10:47 nice rise... but only because the fan base of certain posters have all joined in... it's going to get to a point where they leave and someone's going to be left with a falling share price as the buing pressure is going to disappear. there's no news today that justifies this rise... but as lon as you know and aren't the one left holding the baby for lt to get your money back... never be the last one out! gla.
waterloo01: The highest price I paid for shares was late 2018 at 1.33p so it has some room to run.
shearluc: Agreed, Hopefully a reputable angency demonstrating cost-effectiveness will make some of the NHS accountant types take more notice. If this takes off in China where Ca lung is an even bigger problem then this share will really fly!
waterloo01: htTps:// A study funded by The National Institute for Health Research (NIHR) SBRI programme and led by Leeds University Academic Unit of Health Economics, supported by the NIHR Leeds In-vitro Diagnostics Co-operative (NIHR Leeds MIC), shows that using a blood test in the cancer risk assessment of indeterminate pulmonary nodules is highly cost-effective and could speed the time to diagnosis. At a price point of £70, a blood test known as the EarlyCDT Lung test is more effective compared to CT surveillance with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used. Lung cancer is one of the most prevalent forms of cancer and kills more women than breast and ovarian cancers combined. Five-year survival rates for breast and bowel cancer patients are 86% and 59% respectively. Both of these cancers have screening programmes. Five-year survival for lung cancer, which has no screening programme, is less than 10%. Oncimmune’s Early-CDT Lung is a simple ELISA blood test that measures seven lung cancer-specific antibodies and can be used for the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs). Robust and easy to use, it can be run in any laboratory with standard laboratory equipment and more than 160,000 tests have been sold. A ‘kit’ form of the test was CE marked in May 2017 for distribution to laboratories outside the USA. Dr Helen Radford, Director of Operations, NIHR Leeds MIC, said: “This exciting and important project also included an NHS laboratory validation alongside focus groups with members of the public to understand the patient's perception in early lung cancer screening and how this blood test could help. We look forward to working with Oncimmune in the future.” Dr Adam M. Hill, CEO, Oncimmune Plc said: “The NIHR Leeds MIC was an excellent delivery partner for this project. Their support in bringing the multidisciplinary teams together from across the University and local NHS Trust enabled us to generate further data in support of our adoption discussions with the NHS.”
Oncimmune share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:22:13